MCID: HPR003
MIFTS: 53

Heparin-Induced Thrombocytopenia

Categories: Blood diseases, Immune diseases, Rare diseases

Aliases & Classifications for Heparin-Induced Thrombocytopenia

MalaCards integrated aliases for Heparin-Induced Thrombocytopenia:

Name: Heparin-Induced Thrombocytopenia 54 60 74
Hit 54 60
Heparin-Induced Thrombocytopenia Type 2 60
Heparin-Associated Thrombocytopenia 60
Hat 60

Characteristics:

Orphanet epidemiological data:

60
heparin-induced thrombocytopenia
Inheritance: Not applicable; Age of onset: All ages;

Classifications:



External Ids:

ICD10 via Orphanet 35 D69.5
UMLS via Orphanet 75 C0272285
Orphanet 60 ORPHA3325
UMLS 74 C0272285

Summaries for Heparin-Induced Thrombocytopenia

NIH Rare Diseases : 54 Heparin-induced thrombocytopenia (HIT) is an adverse reaction to the drug heparin resulting in an abnormally low amount of platelets (thrombocytopenia). HIT is usually an immune response which typically occurs 4-10 days after exposure to heparin; it can lead to serious complications and be life-threatening. This condition occurs in up to 5% of those who are exposed to heparin. Characteristic signs of HIT are a drop in platelet count of  greater than 50% and/or the formation of new blood clots during heparin therapy.  The first step of treatment is to discontinue and avoid all heparin products immediately. Often, affected individuals require another medicine to prevent blood clotting (anticoagulants).

MalaCards based summary : Heparin-Induced Thrombocytopenia, also known as hit, is related to thrombosis and catastrophic antiphospholipid syndrome. An important gene associated with Heparin-Induced Thrombocytopenia is F3 (Coagulation Factor III, Tissue Factor), and among its related pathways/superpathways are Collagen chain trimerization and Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers. The drugs Dalteparin and Certoparin have been mentioned in the context of this disorder. Affiliated tissues include testes, b cells and heart, and related phenotypes are thromboembolism and hypercoagulability

Wikipedia : 77 Heparin-induced thrombocytopenia (HIT) is the development of thrombocytopenia (a low platelet count),... more...

Related Diseases for Heparin-Induced Thrombocytopenia

Diseases related to Heparin-Induced Thrombocytopenia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 170)
# Related Disease Score Top Affiliating Genes
1 thrombosis 31.2 F10 F3 SERPINC1
2 catastrophic antiphospholipid syndrome 30.6 CD40LG F3
3 budd-chiari syndrome 30.6 F3 SERPINC1
4 endocarditis 30.6 FCGR2A SERPINC1
5 coronary thrombosis 30.5 F3 SERPINC1
6 pulmonary embolism 30.4 F10 F3 SERPINC1
7 disseminated intravascular coagulation 30.4 F3 SERPINC1
8 purpura 30.4 CD79A F3 SERPINC1
9 sagittal sinus thrombosis 30.3 F3 SERPINC1
10 thrombophilia due to thrombin defect 30.3 F10 F3 SERPINC1
11 marantic endocarditis 30.1 F3 SERPINC1
12 intracranial thrombosis 30.0 F3 SERPINC1
13 protein s deficiency 30.0 F3 SERPINC1
14 antiphospholipid syndrome 29.9 CD40LG F10 F3 SERPINC1
15 thrombocytosis 29.8 F3 SERPINC1
16 peripheral vascular disease 29.7 F3 SERPINC1
17 arteries, anomalies of 29.7 F3 SERPINC1
18 systemic lupus erythematosus 29.7 CD40LG CD79A F3 FCGR2A
19 myocardial infarction 29.7 CD40LG F10 F3 SERPINC1
20 thrombophilia due to activated protein c resistance 29.4 F10 F3 SERPINC1
21 thrombocytopenia 11.6
22 ischemia 10.4
23 essential thrombocythemia 10.4
24 bilateral massive adrenal hemorrhage 10.4
25 acute myocardial infarction 10.3
26 paroxysmal nocturnal hemoglobinuria 10.3
27 thrombotic thrombocytopenic purpura 10.3
28 hemoglobinuria 10.3
29 polycythemia vera 10.2
30 limb ischemia 10.2
31 polycythemia 10.2
32 rere-related disorders 10.2
33 autoimmune disease 10.2
34 amnestic disorder 10.2
35 transient global amnesia 10.2
36 myocarditis 10.2
37 lupus erythematosus 10.2
38 giant cell myocarditis 10.2
39 thrombophilia 10.1 F3 SERPINC1
40 intestinal impaction 10.1 F3 SERPINC1
41 c1q nephropathy 10.1 CD40LG CD79A
42 immunoglobulin g deficiency 10.1 CD40LG CD79A
43 cryofibrinogenemia 10.1 CD40LG CD79A
44 giant hemangioma 10.1 F3 SERPINC1
45 immunoglobulin a deficiency 1 10.1 CD40LG CD79A
46 blue toe syndrome 10.1 F3 SERPINC1
47 primary thrombocytopenia 10.1 CD40LG FCGR2A
48 sporotrichosis 10.1 CD40LG CD79A
49 congenital syphilis 10.1 CD40LG CD79A
50 syphilis 10.1 CD40LG CD79A

Graphical network of the top 20 diseases related to Heparin-Induced Thrombocytopenia:



Diseases related to Heparin-Induced Thrombocytopenia

Symptoms & Phenotypes for Heparin-Induced Thrombocytopenia

Human phenotypes related to Heparin-Induced Thrombocytopenia:

60 (show all 15)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 thromboembolism 60 Very frequent (99-80%)
2 hypercoagulability 60 Very frequent (99-80%)
3 myocardial infarction 60 Occasional (29-5%)
4 pulmonary embolism 60 Occasional (29-5%)
5 venous thrombosis 60 Frequent (79-30%)
6 cerebral ischemia 60 Occasional (29-5%)
7 stroke 60 Occasional (29-5%)
8 arterial thrombosis 60 Frequent (79-30%)
9 increased inflammatory response 60 Occasional (29-5%)
10 autoimmune thrombocytopenia 60 Very frequent (99-80%)
11 abnormal onset of bleeding 60 Very rare (<4-1%)
12 disseminated intravascular coagulation 60 Occasional (29-5%)
13 deep venous thrombosis 60 Frequent (79-30%)
14 increased serum serotonin 60 Frequent (79-30%)
15 mesenteric venous thrombosis 60 Occasional (29-5%)

MGI Mouse Phenotypes related to Heparin-Induced Thrombocytopenia:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.35 CD40LG CD79A F3 FCGR2A SERPINC1
2 immune system MP:0005387 9.02 CD40LG CD79A F3 FCGR2A SERPINC1

Drugs & Therapeutics for Heparin-Induced Thrombocytopenia

Drugs for Heparin-Induced Thrombocytopenia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 68)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dalteparin Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 9005-49-6
2 Certoparin Approved, Investigational Phase 4
3
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 9005-49-6 46507594 772
4
Enoxaparin Approved Phase 4,Phase 2,Phase 3 9005-49-6 772
5
Tinzaparin Approved Phase 4 9041-08-1, 9005-49-6 25244225
6
Fondaparinux Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 104993-28-4
7
Bivalirudin Approved, Investigational Phase 4,Phase 3,Phase 1 128270-60-0 16129704
8
Argatroban Approved, Investigational Phase 4,Phase 3,Phase 2 74863-84-6 152951
9
Nadroparin Approved, Investigational Phase 4
10
Thrombin Approved, Investigational Phase 4,Phase 3,Phase 2
11
Desirudin Approved Phase 4,Phase 2,Phase 3 120993-53-5
12
Lepirudin Approved Phase 4 138068-37-8, 120993-53-5 16132441
13
Warfarin Approved Phase 4,Phase 3,Phase 2,Not Applicable 81-81-2 54678486 6691
14
Calcium Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7440-70-2 271
15
Serine Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 56-45-1 5951
16 Heparin, Low-Molecular-Weight Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
17 Anticoagulants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18 Calcium, Dietary Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
19 Fibrinolytic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 Immunoglobulins Phase 4,Phase 3,Phase 1
21 calcium heparin Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
22 Antibodies Phase 4,Phase 3,Phase 1
23
protease inhibitors Phase 4,Phase 3,Phase 2,Phase 1
24 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
25 Antithrombin III Phase 4,Phase 3,Phase 2,Phase 1
26 Antithrombins Phase 4,Phase 3,Phase 2,Phase 1
27 Serine Proteinase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
28 Immunologic Factors Phase 4,Phase 1
29 Factor Xa Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
30 PENTA Phase 4,Phase 3,Phase 2,Phase 1
31 Hirudins Phase 4,Phase 3,Phase 2,Phase 1
32 Platelet Aggregation Inhibitors Phase 4,Phase 3,Phase 2
33 Thromboplastin Phase 4,Phase 3,Phase 2
34 Liver Extracts Phase 4
35 Platelet Factor 4 Phase 4,Not Applicable
36
Bilirubin Phase 4 635-65-4, 69853-43-6 21252250 5280352
37 Coagulants Phase 4
38
tannic acid Approved Phase 3 1401-55-4
39
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
40
Rivaroxaban Approved Phase 3,Phase 2 366789-02-8
41
Ethanol Approved Phase 3 64-17-5 702
42
Sodium Citrate Approved, Investigational Phase 3 68-04-2
43
Creatine Approved, Investigational, Nutraceutical Phase 2, Phase 3 57-00-1 586
44 Kava Approved, Investigational, Nutraceutical Phase 2, Phase 3 9000-38-8
45
Citric Acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
46 Dermatan Sulfate Phase 3
47 Pharmaceutical Solutions Phase 3
48 Citrate Phase 3
49 Central Nervous System Depressants Phase 3
50 Anti-Infective Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 78)
# Name Status NCT ID Phase Drugs
1 The HIT-TRAP Trial Unknown status NCT00196417 Phase 4 Standard heparin (UFH) versus certoparin (LMWH)
2 Efficacy and Safety of Heparin-coated Surface-treated Polyacrylonitrile Membrane Hemofilter in Critical Ill CRRT Patients Unknown status NCT02355873 Phase 4
3 Impact of Heparin on the Need for Mechanical Ventilation in Neonates Unknown status NCT00196469 Phase 4 heparin
4 Bivalirudin PCI Registry in Heparin Induced Thrombocytopenia/Heparin Induced Thrombocytopenia and Thrombosis Syndrome (HIT/HITTS) Patients Completed NCT00759083 Phase 4 bivalirudin
5 Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin Completed NCT00039858 Phase 4 Argatroban
6 Venous Thromboembolic Prophylaxis After Trauma: Three Times a Day Unfractionated Heparin Versus Twice a Day Enoxaparin Completed NCT01729559 Phase 4 5000 Units unfractionated Heparin Q 8 hr;30mg enoxaparin Q12 hr
7 Nadroparin for the Initial Treatment of Pulmonary Thromboembolism Completed NCT00796692 Phase 4 Nadroparin;Unfractionated heparin(UFH)
8 Study to Evaluate the Mortality Reduction of Enoxaparin in Hospitalized Acutely Ill Medical Receiving Enoxaparin Completed NCT00622648 Phase 4 Enoxaparin;Placebo
9 EXCLAIM:Extended Prophylaxis for Venous ThromboEmbolism (VTE) in Acutely Ill Medical Patients With Prolonged Immobilization Completed NCT00077753 Phase 4 enoxaparin sodium
10 Safety Study of Desirudin, an Anticoagulant for the Prophylaxis of Thrombosis Completed NCT00913133 Phase 4 Desirudin
11 Efficacy of Low Molecular Weight Heparin in Superficial Vein Thrombosis Completed NCT01245998 Phase 4 Dalteparin;Dalteparin
12 Maintaining Patency in Implanted Port Catheters Recruiting NCT02354118 Phase 4
13 Comparison of Low and Intermediate Dose Low-molecular-weight Heparin to Prevent Recurrent Venous Thromboembolism in Pregnancy Recruiting NCT01828697 Phase 4 Low dose nadroparin;Intermediate dose nadroparin;Low dose enoxaparin;Intermediate dose enoxaparin;Low dose dalteparin;Intermediate dose dalteparin;Fixed low dose tinzaparin;Intermediate dose tinzaparin
14 A Comparative Sudy Comparing Argatroban® IV vs Desirudin SC for Suspected HIT With or Without Thrombosis Syndrome Terminated NCT00787332 Phase 4 Desirudin or Argatroban®
15 Argatroban Versus Lepirudin in Critically Ill Patients Terminated NCT00798525 Phase 4 Argatroban;Lepirudin
16 Significance of Antibodies to Heparin/Platelet Factor 4 Complex in Vein Graft Patency and Potential Role of Argatroban for Prevention of Vein Graft Occlusion Terminated NCT01246011 Phase 4 Argatroban and warfarin
17 Maintaining Patency in BioFlo Implanted Port Catheters With Saline Only Flushes Terminated NCT02923830 Phase 4 Saline-only catheter flush
18 Fondaparinux in Patients With Acute Heparin-Induced Thrombocytopenia (HIT) Withdrawn NCT00603824 Phase 4 fondaparinux;argatroban or lepirudin
19 Fondaparinux to Prevent Thrombotic Complications and Graft Failure in Patients Undergoing Coronary Artery Bypass Graft Surgery: The Fonda CABG Study Unknown status NCT00474591 Phase 3 Fondaparinux
20 Efficacy and Safety Study of Argatroban to Treat Heparin-Induced Thrombocytopenia Completed NCT00198588 Phase 3 argatroban
21 Anticoagulant Therapy With Bivalirudin in the Performance of Percutaneous Coronary Intervention in Patients With Heparin-Induced Thrombocytopenia (AT BAT, First Inning) Completed NCT00043940 Phase 3 bivalirudin
22 Angiomax in Patients With HIT/HITTS Type II Undergoing CPB Completed NCT00079508 Phase 3 Angiomax (bivalirudin)
23 Angiomax in Patients With HIT/HITTS Type II Undergoing Off-Pump Coronary Artery Bypass Grafting (CABG) (CHOOSE) Completed NCT00073580 Phase 3 Angiomax (bivalirudin) anticoagulant
24 Heparin 100U/L for Prevention of PVC Complications Completed NCT01131754 Phase 3
25 PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT) Completed NCT00182143 Phase 3 LMWH (Fragmin, dalteparin);Unfractionated Heparin
26 The Use of Fondaparinux in Preventing Thromboembolism in High Risk Trauma Patients Completed NCT00531843 Phase 2, Phase 3 fondaparinux sodium
27 PROSPER: PostpaRtum PrOphylaxiS for PE Randomized Control Trial Pilot Completed NCT01274637 Phase 3 Dalteparin Sodium
28 Study Comparing Desirudin With Heparin to Prevent Vein Clots After Heart and Lung Surgery Completed NCT00329433 Phase 2, Phase 3 Desirudin (Iprivask™);Heparin
29 A Safety and Efficacy Study of BCD-080 Compared to Clexan for Deep Vein Thrombosis Prophylaxis at Orthopedic Surgeries Completed NCT02368314 Phase 3 Sodium Enoxaparine
30 Multi-Center Single Arm Trial to Determine The Effectiveness of Warfarin Therapy Duration For Heparin-Induced Thrombocytopenia (HIT) Recruiting NCT03147638 Phase 3 Warfarin, NOAC
31 An Open-Label, Randomised, Active Controlled, Multi-Centre Phase 3 Study to Evaluate the Safety and Efficacy of Danaparoid vs Argatroban in Treatment of Subjects With Acute HIT Not yet recruiting NCT03809481 Phase 3 Danaparoid Sodium;Argatroban
32 Evaluation of the Efficacy of an inTerdialytic "Ethanol 40% v/v - enoxapaRin 1000 U/mL" Lock solutioN to Prevent Tunnelled Catheter Infections in Chronic Hemodialysis Patients Not yet recruiting NCT03083184 Phase 3 Ethanol;enoxaparin
33 Impact on Morbidity and Mortality of Prophylactic Dosing of Low Molecular Heparin in Child-Pugh B Cirrhotic Patients Suspended NCT02271295 Phase 3 Enoxaparine
34 Rivaroxaban for Treatment of Patients With Suspected or Confirmed Heparin-Induced Thrombocytopenia Terminated NCT01598168 Phase 3 Rivaroxaban
35 Trial of Nebulized Heparin Versus Placebo for Inhalation Trauma Terminated NCT01773083 Phase 3 unfractionated heparin;placebo
36 Clinical Management of Argatroban in Patients With Heparin Induced Thrombocytopenia Type II Completed NCT00861692 Phase 2 argatroban
37 ODiXahip - a Phase IIa Dose Escalating Proof of Principle Trial Completed NCT00839826 Phase 2 Rivaroxaban (BAY59-7939);Enoxaparin
38 Extended Low-Molecular Weight Heparin VTE Prophylaxis in Thoracic Surgery Completed NCT02334007 Phase 1, Phase 2 LMWH: Dalteparin
39 Efficacy and Safety of Apixaban in the Treatment of Heparin Induced Thrombocytopenia (HIT) Recruiting NCT03594045 Phase 2 Apixaban
40 Addition of Enoxaparin to Neoadjuvant Chemoradiation of Esophageal Cancer Recruiting NCT03254511 Phase 2 Enoxaparin Sodium 40 MG/0.2 ML Subcutaneous Injectable;Chemotherapeutic Combinations
41 Aneurysmal Subarachnoid Hemorrhage Trial RandOmizing Heparin Recruiting NCT02501434 Phase 2 Continuous Low-Dose IV Unfractionated Heparin Infusion
42 Heparin Anticoagulation in Septic Shock Recruiting NCT03378466 Phase 2 Unfractionated heparin
43 Catheter-Related Early Thromboprophylaxis With Enoxaparin (CRETE) Trial Recruiting NCT03003390 Phase 2 Enoxaparin
44 Fondaparinux for the Treatment of Heparin-Induced Thrombocytopenia (HIT) Terminated NCT00673439 Phase 2 fondaparinux;warfarin
45 Heparin-Induced Thrombocytopenia Score Card Study Completed NCT00489437 Phase 1
46 Pilot Dose Finding and Pharmacokinetic Study of Fondaparinux in Children With Thrombosis Completed NCT00412464 Phase 1 Fondaparinux
47 Bivalirudin vs Heparin in ECMO Patients Not yet recruiting NCT03707418 Phase 1 Heparin Sodium;Bivalirudin Injection [Angiomax]
48 Validating 4Ts for Heparin Induced Thrombocytopenia (HIT) Unknown status NCT00946400
49 A Study on the Prevalence of Heparin-Induced Thrombocytopenia in Cardiovascular Patients Unknown status NCT00198575
50 Generation of Heparin-induced Thrombocytopenia (HIT)-Antibodies Without Prior Heparin Exposure Unknown status NCT01102790

Search NIH Clinical Center for Heparin-Induced Thrombocytopenia

Genetic Tests for Heparin-Induced Thrombocytopenia

Anatomical Context for Heparin-Induced Thrombocytopenia

MalaCards organs/tissues related to Heparin-Induced Thrombocytopenia:

42
Testes, B Cells, Heart, Lung, Liver, Brain, Skin

Publications for Heparin-Induced Thrombocytopenia

Articles related to Heparin-Induced Thrombocytopenia:

(show top 50) (show all 4972)
# Title Authors Year
1
Transient Expression of Interleukin-21 in the Second Hit of Acute Pancreatitis May Potentiate Immune Paresis in Severe Acute Pancreatitis. ( 30451792 )
2019
2
The cyclical hit model: how paligenosis might establish the mutational landscape in Barrett's esophagus and esophageal adenocarcinoma. ( 31021922 )
2019
3
A case-report of successful use of thromboelastography to manage anticoagulation therapy in a patient with concomitant catastrophic antiphospholipid syndrome and heparin-induced thrombocytopenia. ( 31090599 )
2019
4
A Patient With Remote Heparin-Induced Thrombocytopenia and Antiphospholipid Syndrome Requiring Cardiopulmonary Bypass: Do Current Guidelines Apply? ( 29871549 )
2019
5
Sex and Estrous Cycle Effects on Anxiety- and Depression-Related Phenotypes in a Two-Hit Developmental Stress Model. ( 31031589 )
2019
6
Drug Discovery for Chagas Disease: Impact of Different Host Cell Lines on Assay Performance and Hit Compound Selection. ( 31108888 )
2019
7
Timely Use of Biologics in Early Crohn's Disease: The Return of "Hit Hard and Early"? ( 30725301 )
2019
8
A "double hit" model of cystic kidney disease. ( 31010483 )
2019
9
Post-traumatic stress disorder and depression symptoms of adolescents survived from a seriously-hit area in China: A 3-year follow-up study. ( 30677716 )
2019
10
Primary Cutaneous Diffuse Large B-Cell Lymphoma of the Upper Limb: Double Hit/Double Expressor with CNS Involvement: From Hospice to Remission. ( 30881709 )
2019
11
A double-hit pre-eclampsia model results in sex-specific growth restriction patterns. ( 30683649 )
2019
12
Newly Diagnosed Metastatic Intracranial Ependymoma in Children: Frequency, Molecular Characteristics, Treatment, and Outcome in the Prospective HIT Series. ( 30850560 )
2019
13
Increased risk of heparin induced thrombocytopenia and thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation. ( 30478722 )
2019
14
Transformation of follicular lymphoma to double-hit lymphoma during adjuvant chemotherapy for concurrent ovarian carcinoma. ( 31104212 )
2019
15
Prospective evaluation of HEP and 4Ts scores in Chinese patients with suspected heparin-induced thrombocytopenia. ( 30994533 )
2019
16
Acute non-heparin-induced thrombocytopenia during hemodiafiltration in a patient with multiple myeloma. ( 30997067 )
2019
17
Neutrophil and Monocyte Counts in Heparin-Induced Thrombocytopenia. ( 31005061 )
2019
18
Timeline of heparin-induced thrombocytopenia seroconversion in serial plasma samples tested using an automated latex immunoturbidimetric assay. ( 31050876 )
2019
19
Laboratory diagnosis of heparin-induced thrombocytopenia. ( 31069988 )
2019
20
Use of a whole-cell ELISA to detect additional antibodies in setting of suspected heparin-induced thrombocytopenia. ( 31107976 )
2019
21
Heparin-Induced Thrombocytopenia in Infants after Heart Surgery. ( 29605959 )
2019
22
PIFA PLUSS P4 Assay for Screening of Heparin-Induced Thrombocytopenia. ( 30085261 )
2019
23
Dabigatran as a Treatment Option for Heparin-Induced Thrombocytopenia. ( 30285276 )
2019
24
Plasma exchange for heparin-induced thrombocytopenia in patients on extracorporeal circuits: A challenging case and a survey of the field. ( 30407650 )
2019
25
Heparin-Induced Thrombocytopenia: A Review for Cardiac Anesthesiologists and Intensivists. ( 30502310 )
2019
26
Prospective Evaluation of a Rapid Functional Assay for Heparin-Induced Thrombocytopenia Diagnosis in Critically Ill Patients. ( 30507843 )
2019
27
Limited impact of clinician education on reducing inappropriate PF4 testing for heparin-induced thrombocytopenia. ( 30612329 )
2019
28
An international external quality assessment for laboratory diagnosis of heparin-induced thrombocytopenia. ( 30640980 )
2019
29
Fondaparinux in heparin-induced thrombocytopenia: A decade's worth of clinical experience. ( 30656269 )
2019
30
Successful Use of Cangrelor and Heparin for Cardiopulmonary Bypass in a Patient With Heparin-Induced Thrombocytopenia and End-Stage Renal Disease: A Case Report. ( 30688681 )
2019
31
A platelet viability assay (PVA) for the diagnosis of heparin-induced thrombocytopenia. ( 30693813 )
2019
32
False-Negative Platelet Factor 4 Antibodies and Serotonin Release Assay and the Utility of Repeat Testing in the Diagnosis of Heparin-Induced Thrombocytopenia and Thrombosis. ( 30729049 )
2019
33
Heparin-Induced Thrombocytopenia: Finding the Needle in the Haystack. ( 30768506 )
2019
34
High-dose Intravenous Immunoglobulin to Treat Spontaneous Heparin-induced Thrombocytopenia Syndrome. ( 30773806 )
2019
35
Development of an algorithm for the systematic evaluation of patients with suspected heparin-induced thrombocytopenia. ( 30790161 )
2019
36
Evaluation of STic Expert® HIT Kit and Its Comparison with ID-PaGIA™ Test in Suspected Heparin-Induced Thrombocytopenia. ( 30828164 )
2019
37
Autoimmune Heparin-Induced Thrombocytopenia: Treatment Obstacles and Challenging Length of Stay. ( 30850576 )
2019
38
Heparin-induced thrombocytopenia during extracorporeal life support: incidence, management and outcomes. ( 30854309 )
2019
39
Routine monitoring for heparin-induced thrombocytopenia following lower limb arthroplasty: Is it necessary? A prospective study in a UK district general hospital. ( 30878232 )
2019
40
Neutrophil activation and NETosis are the major drivers of thrombosis in heparin-induced thrombocytopenia. ( 30899022 )
2019
41
Autoimmune heparin-induced thrombocytopenia and venous limb gangrene after aortic dissection repair: in vitro and in vivo effects of intravenous immunoglobulin. ( 30903805 )
2019
42
Mesenteric Ischemia Caused by Heparin-induced Thrombocytopenia: A Case Report. ( 30911456 )
2019
43
Cleavage of anti-PF4/Heparin IgG by a bacterial protease and potential benefit in heparin-induced thrombocytopenia. ( 30917957 )
2019
44
Evaluation of heparin induced thrombocytopenia using probability scores in a mechanical circulatory support population. ( 30919254 )
2019
45
Refractory Heparin-Induced Thrombocytopenia With Cerebral Venous Sinus Thrombosis Treated With IVIg, Steroids, and a Combination of Anticoagulants: A Case Report. ( 30939936 )
2019
46
Successful Treatment of Severe Heparin-induced Thrombocytopenia with Intravenous Immunoglobulin, Platelet Transfusion and Rivaroxaban: A Case Report. ( 30961783 )
2019
47
Acute renal failure due to bilateral renal vein thromboses: A rare complication of heparin-induced thrombocytopenia. ( 30971604 )
2019
48
Heparin-induced thrombocytopenia in patients on extracorporeal membrane oxygenation and the role of a heparin-bonded circuit. ( 30977431 )
2019
49
Evaluation of a rapid and automated heparin-induced thrombocytopenia immunoassay. ( 30986338 )
2019
50
Four Limb Ischemia: A Severe Case of Heparin Induced Thrombocytopenia. ( 30988593 )
2019

Variations for Heparin-Induced Thrombocytopenia

Expression for Heparin-Induced Thrombocytopenia

Search GEO for disease gene expression data for Heparin-Induced Thrombocytopenia.

Pathways for Heparin-Induced Thrombocytopenia

GO Terms for Heparin-Induced Thrombocytopenia

Cellular components related to Heparin-Induced Thrombocytopenia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.43 CD40LG CD79A F10 F3 FCGR2A SERPINC1
2 intrinsic component of external side of plasma membrane GO:0031233 8.62 F10 F3

Biological processes related to Heparin-Induced Thrombocytopenia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 blood coagulation GO:0007596 9.33 F10 F3 SERPINC1
2 B cell differentiation GO:0030183 9.32 CD40LG CD79A
3 B cell proliferation GO:0042100 9.26 CD40LG CD79A
4 blood coagulation, extrinsic pathway GO:0007598 8.96 F10 F3
5 hemostasis GO:0007599 8.8 F10 F3 SERPINC1

Molecular functions related to Heparin-Induced Thrombocytopenia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 phospholipid binding GO:0005543 8.96 F10 F3
2 protease binding GO:0002020 8.62 F3 SERPINC1

Sources for Heparin-Induced Thrombocytopenia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....